Department of Pharmacy, Cleveland Clinic, Cleveland, Ohio, USA.
Department of Pharmacy and Transplant Institute, Henry Ford Health, Detroit, MI, USA.
Clin Transplant. 2023 Sep;37(9):e15079. doi: 10.1111/ctr.15079. Epub 2023 Jul 21.
Lung transplant recipients are at an increased risk for Clostridioides difficile infection (CDI), and those who develop CDI post-transplant can have worsened outcomes including graft failure and death. We sought to describe the efficacy and safety of primary CDI prophylaxis with oral vancomycin among 86 adult lung transplant recipients. Overall, we observed a 9.3% (8/86) incidence of CDI among patients receiving prophylaxis, with the majority of infections occurring a median of 25 days after completion of prophylaxis. Furthermore, we observed a 4.7% incidence of VRE infection/colonization. Opportunities exist to optimize the duration of CDI prophylaxis to balance the benefits and risks in lung transplant recipients.
肺移植受者发生艰难梭菌感染（CDI）的风险增加，移植后发生 CDI 的患者预后更差，包括移植物失功和死亡。我们旨在描述 86 例成人肺移植受者中口服万古霉素预防 CDI 的疗效和安全性。总体而言，我们观察到接受预防治疗的患者中有 9.3%（8/86）发生 CDI，大多数感染发生在预防治疗完成后中位数 25 天。此外，我们观察到 4.7%的 VRE 感染/定植发生率。存在优化 CDI 预防持续时间的机会，以平衡肺移植受者的获益和风险。
